Sattva Sukun files routine FY26 results and rights-issue utilisation report
The board signed off on audited results and a statement confirming rights-issue proceeds were spent as planned. No surprises.
— 2 earlier stories on Sattva Sukun Lifecare Ltd. →What's new
- Board approved audited standalone and consolidated financial results for Q4 and FY26.
- Auditor reports were presented to the board.
- A deviation statement on the utilisation of rights-issue proceeds was filed, showing funds were used as intended.
Why this matters
This is the standard annual update from a tiny company. The new data gives fundamental analysts the latest earnings and balance-sheet snapshot, but the filing contains no guidance, profit warning, or strategic shift. For a ₹29 crore market-cap stock, any price movement will be about the numbers themselves.
What we're watching
- The actual FY26 profit and loss figures once they are parsed by the market.
- Any significant movement in the stock price post-results, though the nano-cap size suggests volatility.
- The next quarterly update to see if the trend continues.
The full read
Sattva Sukun Lifecare's board signed off on its audited FY26 results. For a company with a ₹29 crore market cap, this is the main annual disclosure. It landed without drama. The filing bundles the quarterly and full-year numbers, auditor sign-offs, and a statement confirming its rights-issue proceeds were spent as planned. There is no guidance, no warning, and no strategic pivot. The only new information is the financial data itself. For a stock this small, the reaction will be in the trading, not the filing.
Questions answered
- What did the board meeting approve?
- The board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the accompanying auditor reports.
- Was there any issue with the rights-issue money?
- No. The filing includes a deviation statement on the rights-issue proceeds, which indicates the funds were utilised as per the stated plan.
- Why is this considered a routine filing?
- It is a periodic compliance disclosure for annual results, which the market anticipates. There were no unexpected profit warnings, guidance updates, or material strategic announcements.
- How big is Sattva Sukun Lifecare?
- It is a nano-cap company with a market capitalisation of ₹29 crore.
Story so far
All notes on SATTVASUKU →- 4 Jun 2026 · 8:31 PM IST Sattva Sukun files routine FY26 results and rights-issue utilisation report
- today Sattva Sukun's profit plummets 92% after rights issue
- today Sattva Sukun reports FY26; rights-issue proceeds spent as planned